Moomoo AI 已提取核心信息
Exicure, Inc., a biotechnology company listed on NASDAQ under the ticker XCUR, has been involved in a significant transaction according to a Schedule 13D/A filing with the U.S. Securities and Exchange Commission. The amendment, filed on March 4, 2024, details the actions of two major shareholders, CBI USA, Inc. and DGP Co., Ltd., both of which have reported substantial ownership stakes in Exicure. As of February 29, 2024, DGP Co., Ltd. holds 35.4% of Exicure's outstanding common stock, while CBI USA, Inc. owns 9.5%. Collectively, they control 44.8% of the company's shares. The filing reveals that DGP Co., Ltd. entered into a stock purchase agreement with OverdigmK Co., Ltd., a company based in the Republic of Korea, to sell 3,400,000 shares of Exicure for 6 billion...Show More
Exicure, Inc., a biotechnology company listed on NASDAQ under the ticker XCUR, has been involved in a significant transaction according to a Schedule 13D/A filing with the U.S. Securities and Exchange Commission. The amendment, filed on March 4, 2024, details the actions of two major shareholders, CBI USA, Inc. and DGP Co., Ltd., both of which have reported substantial ownership stakes in Exicure. As of February 29, 2024, DGP Co., Ltd. holds 35.4% of Exicure's outstanding common stock, while CBI USA, Inc. owns 9.5%. Collectively, they control 44.8% of the company's shares. The filing reveals that DGP Co., Ltd. entered into a stock purchase agreement with OverdigmK Co., Ltd., a company based in the Republic of Korea, to sell 3,400,000 shares of Exicure for 6 billion Korean Won, equivalent to $1.32 per share. The initial 10% of the sale closed on the date of the agreement, with the remaining 90% expected to close by June 30, 2024. Additionally, CBI USA, Inc. has loaned 340,000 shares to DGP to facilitate the initial closing of the transaction. The reporting persons have expressed their belief that the current composition of Exicure's board of directors represents their interests as substantial stockholders, and they plan to continue working with the board to seek financing and address outstanding deficiencies with Nasdaq listing and SEC reporting requirements.
根据向美国证券交易委员会提交的附表13D/A文件，在纳斯达克上市的股票代码为XCUR的生物技术公司Exicure, Inc. 已参与一项重大交易。该修正案于2024年3月4日提交，详细介绍了两位主要股东——CBI USA, Inc.和DGP有限公司的行动，这两家公司都报告了Exicure的大量所有权。截至2024年2月29日，DGP有限公司持有Exicure已发行普通股的35.4％，而CBI USA, Inc.持有9.5％的股份。他们共同控制了公司44.8％的股份。文件显示，DGP有限公司与总部位于大韩民国的OverDigMK有限公司签订了股票购买协议，以60亿韩元（相当于每股1.32美元）的...展开全部
根据向美国证券交易委员会提交的附表13D/A文件，在纳斯达克上市的股票代码为XCUR的生物技术公司Exicure, Inc. 已参与一项重大交易。该修正案于2024年3月4日提交，详细介绍了两位主要股东——CBI USA, Inc.和DGP有限公司的行动，这两家公司都报告了Exicure的大量所有权。截至2024年2月29日，DGP有限公司持有Exicure已发行普通股的35.4％，而CBI USA, Inc.持有9.5％的股份。他们共同控制了公司44.8％的股份。文件显示，DGP有限公司与总部位于大韩民国的OverDigMK有限公司签订了股票购买协议，以60亿韩元（相当于每股1.32美元）的价格出售Exicure的34万股股票。最初的10％的销售在协议签订之日结束，其余90％的销售预计将在2024年6月30日之前完成。此外，CBI USA, Inc.已向DGP贷款了34万股股票，以促进交易的初步完成。申报人表示，他们相信Exicure董事会目前的组成代表了他们作为主要股东的利益，他们计划继续与董事会合作，寻求融资，解决纳斯达克上市和美国证券交易委员会报告要求方面的突出缺陷。
有用
没用
